Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clevudine + adefovir
- Development stage
- Unknown
- Lead developer
- Bukwang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antiviral therapy consisting of clevudine and adefovir used for the treatment of hepatitis B virus (HBV) infection. The combination has demonstrated potent antiviral activity with a better resistance profile compared to clevudine monotherapy. Clevudine is a nucleoside analog already approved for HBV in South Korea and the Philippines, while adefovir is another established antiviral medication for HBV treatment.
- Brand names
- LevovirRevovirHepsera
- Other names
- clevudine and adefovir combinationclevudine plus adefovirclevudine and adefovir dipivoxil combination
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on clevudine + adefovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clevudine + adefovir.